Cyramza

Active Ingredient(s): Ramucirumab
FDA Approved: * April 21, 2014
Pharm Company: * ELI LILLY AND CO
Category: Cancer

Ramucirumab[1] (LY3009806, IMC-1121B, trade name Cyramza[2][3]) is a fully human monoclonal antibody (IgG1) developed for the treatment of solid tumors. This drug was developed by ImClone Systems Inc. It was isolated from a native phage display library from Dyax. Contents 1 Approved uses 2 Contraindications 3 Side effects 4 Interactions 5 Pharmacology 5.1 Mechanism of action 6 Clinical trials 7 References 8 External links Approved uses... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.
1 Discussion

Dosage List

Cyramza 10 mg/ml Intravenous Solution

NDC: 0002-7669

Labeler:

Eli Lilly and Company

Cyramza 10 mg/ml Intravenous Solution

NDC: 0002-7678

Labeler:

Eli Lilly and Company

Dosage List

Popular Topics